Tactile Systems Technology, Inc. reported its financial results for the first quarter ended March 31, 2025, on May 5, 2025. Total revenue for the quarter increased marginally by 0.3% to $61.3 million, compared to $61.1 million in Q1 2024. Airway clearance revenue increased by 22%, while lymphedema revenue decreased by 3%.
Gross profit for Q1 2025 increased by 4% to $45.3 million, with a gross margin of 74%, up from 71% in the prior year. However, operating expenses increased by 8% to $49.9 million due to planned strategic investments, resulting in an operating loss of $4.5 million, compared to an operating loss of $3.0 million in Q1 2024.
The company reported a net loss of $3.0 million, or $(0.13) per diluted share, compared to a net loss of $2.2 million, or $(0.09) per diluted share, in Q1 2024. Adjusted EBITDA for the quarter was a loss of $0.3 million, a decline from a positive Adjusted EBITDA of $1.0 million in Q1 2024.
Tactile Medical updated its full-year 2025 total revenue guidance to a range of $309 million to $315 million, representing 5% to 8% year-over-year growth, a reduction from its prior guidance of $316 million to $322 million. The company also lowered its full-year 2025 adjusted EBITDA guidance to a range of $32 million to $34 million, down from the previous expectation of $35 million to $37 million.
During the first quarter, the company repurchased $10.0 million of its stock under the existing program. As of March 31, 2025, $16.5 million remained available under the $30.0 million share repurchase program.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.